Vyne Therapeutics Inc reports results for the quarter ended in January - Earnings Summary

YARROW BIOSCIENCE

09/05/2024 13:58

* Vyne Therapeutics Inc  VYNE.OQ  reported a quarterly
adjusted
loss of 15 cents​​ per share for the quarter ended in January,
higher than the same quarter last year, when the company
reported EPS of $-1.74.  The lone analyst forecast for the
quarter was for a loss of 24 cents per share. 
    * Revenue fell 1% to $98.00 thousand from a year ago;
analysts
expected $100.00 thousand. 
    * Vyne Therapeutics Inc's reported EPS for the quarter was a
loss
of 15 cents​.
    * The company reported a quarterly loss of $6.25 million.
    * Vyne Therapeutics Inc shares had fallen by 11.4% this
quarter and gained 16.7% so far this year.

FORECAST CHANGES
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Vyne Therapeutics
Inc is $5.75 
This summary was machine generated from LSEG data May 9 at 12:58
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.24          -0.15          Beat
 Dec. 31 2023      -0.50          -0.20          Beat
 Sep. 30 2023      -0.76          -2.01          Missed
 Jun. 30 2023      -1.99          -3.09          Missed